Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355823 | 0.83 | LMNA (0.39) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL17833829 | 0.83 | ALOX5 (0.40) | MEN1ALDH1A1MAPTKMT2ANPC1 | |
| SCHEMBL12923619 | 0.81 | MEN1 (0.39) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15357412 | 0.81 | — | — | |
| SCHEMBL17553408 | 0.80 | — | — | |
| SCHEMBL15357330 | 0.78 | ALDH1A1 (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12452198 | 0.77 | MAPT (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL10293850 | 0.74 | PARG (0.31) | — | |
| SCHEMBL19269203 | 0.72 | KDM4E (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19269204 | 0.71 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180149654-A1 | BIOSENSORS AND METHODS FOR DETECTION OF LYSOPHOSPHATIDIC ACID FOR SIGNALING OF OVARIAN CANCER | ECONOUS SYSTEMS INC. (CA) | 2018-05-31 | — | — | US | disclosed |
| US-20170258933-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF MOLECULES INTO LIVE CELLS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-09-14 | — | — | US | disclosed |
| US-9662404-B2 | Compositions and methods for the delivery of molecules into live cells | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-05-30 | — | — | US | disclosed |
| US-9329185-B2 | Sulfonate compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150099690-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF MOLECULES INTO LIVE CELLS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-04-09 | — | — | US | disclosed |
| US-20140275526-A1 | SULFONATE COMPOUNDS | UNIVERSITY OF MASSACHUSETTS (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099690-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF MOLECULES INTO LIVE CELLS | ANXA6, ANXA5, ANXA1 | KDM4E 4532/4885MEN1 878/4885ALDH1A1 4878/4885 |
| US-20180149654-A1 | BIOSENSORS AND METHODS FOR DETECTION OF LYSOPHOSPHATIDIC ACID FOR SIGNALING OF OVARIAN CANCER | LPAR6, LPAR2, LPAR1 | KDM4E 2848/4885MEN1 1949/4885ALDH1A1 3699/4885 |
| US-20170258933-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF MOLECULES INTO LIVE CELLS | ANXA6, ANXA5, ANXA1 | KDM4E 4532/4885MEN1 878/4885ALDH1A1 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.